{"id":"https://openalex.org/W4312306563","doi":"https://doi.org/10.1145/3545729.3545766","title":"Thyroid Dland Disorders Associated with Combination of Antiangiogenic Agents and Immune Checkpoint Inhibitors: A Pharmacovigilance Study","display_name":"Thyroid Dland Disorders Associated with Combination of Antiangiogenic Agents and Immune Checkpoint Inhibitors: A Pharmacovigilance Study","publication_year":2022,"publication_date":"2022-05-13","ids":{"openalex":"https://openalex.org/W4312306563","doi":"https://doi.org/10.1145/3545729.3545766"},"language":"en","primary_location":{"id":"doi:10.1145/3545729.3545766","is_oa":false,"landing_page_url":"https://doi.org/10.1145/3545729.3545766","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"2022 6th International Conference on Medical and Health Informatics","raw_type":"proceedings-article"},"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006966004","display_name":"Lujie Zhuge","orcid":null},"institutions":[{"id":"https://openalex.org/I114539943","display_name":"Zhejiang Chinese Medical University","ror":"https://ror.org/04epb4p87","country_code":"CN","type":"education","lineage":["https://openalex.org/I114539943"]}],"countries":["CN"],"is_corresponding":true,"raw_author_name":"Lujie Zhuge","raw_affiliation_strings":["Zhejiang Chinese Medical University, China"],"affiliations":[{"raw_affiliation_string":"Zhejiang Chinese Medical University, China","institution_ids":["https://openalex.org/I114539943"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5006966004"],"corresponding_institution_ids":["https://openalex.org/I114539943"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.17924582,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":"183","last_page":"188"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11492","display_name":"Academic integrity and plagiarism","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/3311","display_name":"Safety Research"},"field":{"id":"https://openalex.org/fields/33","display_name":"Social Sciences"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11492","display_name":"Academic integrity and plagiarism","score":0.9818999767303467,"subfield":{"id":"https://openalex.org/subfields/3311","display_name":"Safety Research"},"field":{"id":"https://openalex.org/fields/33","display_name":"Social Sciences"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9814000129699707,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.9620000123977661,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adverse-event-reporting-system","display_name":"Adverse Event Reporting System","score":0.8707530498504639},{"id":"https://openalex.org/keywords/pharmacovigilance","display_name":"Pharmacovigilance","score":0.846248209476471},{"id":"https://openalex.org/keywords/medicine","display_name":"Medicine","score":0.838981032371521},{"id":"https://openalex.org/keywords/thyroid","display_name":"Thyroid","score":0.6683189868927002},{"id":"https://openalex.org/keywords/meddra","display_name":"MedDRA","score":0.5688469409942627},{"id":"https://openalex.org/keywords/adverse-effect","display_name":"Adverse effect","score":0.5552864074707031},{"id":"https://openalex.org/keywords/thyroiditis","display_name":"Thyroiditis","score":0.5373382568359375},{"id":"https://openalex.org/keywords/internal-medicine","display_name":"Internal medicine","score":0.5063852071762085},{"id":"https://openalex.org/keywords/odds-ratio","display_name":"Odds ratio","score":0.44760459661483765},{"id":"https://openalex.org/keywords/oncology","display_name":"Oncology","score":0.3767794370651245}],"concepts":[{"id":"https://openalex.org/C2777105317","wikidata":"https://www.wikidata.org/wiki/Q4686710","display_name":"Adverse Event Reporting System","level":3,"score":0.8707530498504639},{"id":"https://openalex.org/C57658597","wikidata":"https://www.wikidata.org/wiki/Q1550789","display_name":"Pharmacovigilance","level":3,"score":0.846248209476471},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.838981032371521},{"id":"https://openalex.org/C526584372","wikidata":"https://www.wikidata.org/wiki/Q16399","display_name":"Thyroid","level":2,"score":0.6683189868927002},{"id":"https://openalex.org/C199475168","wikidata":"https://www.wikidata.org/wiki/Q1539689","display_name":"MedDRA","level":4,"score":0.5688469409942627},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5552864074707031},{"id":"https://openalex.org/C2778696486","wikidata":"https://www.wikidata.org/wiki/Q11835644","display_name":"Thyroiditis","level":3,"score":0.5373382568359375},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5063852071762085},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.44760459661483765},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3767794370651245}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1145/3545729.3545766","is_oa":false,"landing_page_url":"https://doi.org/10.1145/3545729.3545766","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"2022 6th International Conference on Medical and Health Informatics","raw_type":"proceedings-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.7300000190734863,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":20,"referenced_works":["https://openalex.org/W1996239270","https://openalex.org/W2004405850","https://openalex.org/W2043402979","https://openalex.org/W2064893052","https://openalex.org/W2066671159","https://openalex.org/W2097995306","https://openalex.org/W2124427232","https://openalex.org/W2125616358","https://openalex.org/W2160834915","https://openalex.org/W2296047035","https://openalex.org/W2396885039","https://openalex.org/W2400334483","https://openalex.org/W2594042408","https://openalex.org/W2760410509","https://openalex.org/W2774557779","https://openalex.org/W2912708591","https://openalex.org/W2980987136","https://openalex.org/W2984466790","https://openalex.org/W3080850044","https://openalex.org/W6665569923"],"related_works":["https://openalex.org/W4283372525","https://openalex.org/W4393344886","https://openalex.org/W4390816718","https://openalex.org/W3045268911","https://openalex.org/W4391047716","https://openalex.org/W1965446264","https://openalex.org/W2131576700","https://openalex.org/W2152948022","https://openalex.org/W3087669131","https://openalex.org/W4396619657"],"abstract_inverted_index":{"Purpose:":[0],"Immune":[1],"checkpoint":[2],"inhibitors":[3],"(ICIs),":[4],"including":[5,92],"anti-PD-1/L1":[6],"therapy":[7,309],"and":[8,30,49,74,80,144,166,173,177,179,198,232,274,296],"anti-CTLA-4":[9],"therapy,":[10],"were":[11,72,97,147,175,227,302],"reported":[12],"with":[13,209,240],"thyroid":[14,46,163,199,233,261,291,323],"gland":[15,47,90,164,200,234,262,292,324],"disorders":[16,48,263,293],"adverse":[17,64],"events.":[18],"Recently,":[19],"the":[20,26,43,50,57,62,77,100,124,128,137,155,167,182,210,287,307],"FDA":[21,63],"announced":[22],"a":[23,38,121,241],"warning":[24],"that":[25],"combination":[27,58,308],"of":[28,52,127,139,162,260,290,294,322],"navolumab":[29],"cabozantinib":[31],"can":[32],"cause":[33],"adrenal":[34],"insufficiency.":[35],"We":[36,107],"performed":[37],"pharmacovigilance":[39],"study":[40,190],"to":[41,149,193,278,314],"analyze":[42,150],"association":[44],"between":[45,196,229,272],"use":[51],"ICI,":[53],"anti-angiogenic":[54,220,230,275,297,331],"agents":[55,298],"or":[56,330],"treatment":[59],"by":[60,99],"mining":[61],"events":[65],"reporting":[66,112],"system":[67],"(FAERS)":[68,87],"database.":[69,88],"Methods:":[70],"Data":[71],"searched":[73],"analyzed":[75],"in":[76],"US":[78],"Food":[79],"Drug":[81],"Administration":[82],"Adverse":[83],"Event":[84],"Reporting":[85],"System":[86],"Thyroid":[89],"disorders,":[91,165,235],"hypothyroidism,":[93],"hyperthyroidism,":[94,171],"autoimmune":[95],"thyroiditis,":[96],"defined":[98,119],"Medical":[101],"Dictionary":[102],"for":[103,132,170,185,219,250],"Regulatory":[104],"Activities":[105],"(MedDRA).":[106],"conducted":[108],"disproportionality":[109,183],"analysis":[110],"using":[111,328],"odds":[113],"ratio":[114],"(ROR).":[115],"The":[116],"result":[117],"was":[118,207,238,310],"as":[120],"signal":[122,212,243],"if":[123],"lower":[125],"limit":[126],"95%":[129],"confidence":[130],"interval":[131],"ROR":[133],"is":[134],"over":[135],"2,":[136],"number":[138,169],"cases":[140,161,168],"\u22653.":[141],"And":[142,267],"additive":[143],"multiplicative":[145],"models":[146],"applied":[148],"drug":[151],"interactions.":[152],"Results:":[153],"In":[154,181,282,312],"FAERS":[156],"database,":[157],"we":[158,254,268,285,318],"identified":[159],"2862":[160],"hypothyroidism":[172,237],"thyroiditis":[174,206],"767":[176],"1579":[178],"556.":[180],"analysis,":[184],"ICI":[186,273],"drugs":[187,221,231,276],"group,":[188,222],"our":[189,283],"detected":[191],"moderate":[192],"strong":[194],"signals":[195,226,259,305],"ICIs":[197,295,329],"disorders.":[201],"Among":[202],"these":[203],"subgroups,":[204],"ICI-related":[205],"associated":[208],"strongest":[211],"(ROR":[213,244],"23.09":[214],"[95%":[215,246],"CI":[216,247],"21.08-25.28]).":[217],"As":[218,249],"however,":[223,300],"very":[224],"weak":[225],"found":[228,239],"only":[236],"significant":[242],"4.87":[245],"4.60-5.16]).":[248],"combined":[251],"regimen":[252],"groups,":[253],"didn't":[255,269],"identify":[256],"significantly":[257],"increased":[258,288,304],"than":[264],"monotherapy":[265],"treatment.":[266],"find":[270],"interactions":[271],"according":[277],"additive/multiplicative":[279],"models.":[280],"Conclusion:":[281],"study,":[284],"confirmed":[286],"risk":[289,326],"monotherapy,":[299],"there":[301],"no":[303],"when":[306,327],"used.":[311],"order":[313],"prevent":[315],"serious":[316],"outcomes,":[317],"should":[319],"be":[320],"aware":[321],"disorders'":[325],"agents.":[332]},"counts_by_year":[],"updated_date":"2025-11-06T03:46:38.306776","created_date":"2025-10-10T00:00:00"}